Lindbrook Capital, LLC Supernus Pharmaceuticals, Inc. Transaction History
Lindbrook Capital, LLC
- $1.18 Billion
- Q3 2024
A detailed history of Lindbrook Capital, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 83 shares of SUPN stock, worth $3,199. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83
Previous 66
25.76%
Holding current value
$3,199
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding SUPN
# of Institutions
283Shares Held
60.6MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$401 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$236 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$196 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$111 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$101 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.06B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...